| Grant number: | 16/13639-8 |
| Support Opportunities: | Scholarships in Brazil - Doctorate (Direct) |
| Start date: | October 01, 2016 |
| End date: | January 31, 2019 |
| Field of knowledge: | Physical Sciences and Mathematics - Chemistry - Analytical Chemistry |
| Principal Investigator: | Maria Eugênia Queiroz Nassur |
| Grantee: | Camila Marchioni |
| Host Institution: | Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil |
Abstract Endocannabinoids (eCBs) are neurotransmitters derived from arachidonic acid. eCBs bind to cannabinoid receptors and participate in several brain functions, like motor functions. Alterations in the endocannabinoid system in patients with Parkinson´s Disease (PD) have been evaluated by determination of anandamide (AEA) and 2-arachidonoyl glycerol (2AG), two major eCBs, in biological samples. Recently, cannabidiol (CBD), a derivative of Cannabis sativa, has been evaluated for the treatment of PD in patients with psychotic symptoms. Liquid chromatography-Tandem mass spectrometry is considered the reference analytical technique to determine eCBS and cannabinoid in biological samples. Column switching LC-MS/MS allows automation of the analysis by hyphenating sample biological preparation (preconcentration of analytes and removal of endogenous components) with the chromatographic system (chromatographic separation and detection), which shortens analysis time, reduces the amount of biological sample and the volume of organic solvents, and increases analytical selectivity and sensitivity. We have developed the online column switching liquid chromatography Tandem mass spectrometry (UHPLC-MS/MS) method to determine AEA and 2AG in plasma and cerebrospinal fluid samples from patients with PD. Our future aim is to develop an online column switching UHPLC-MS/MS method that uses a monolithic MIP column in the first dimension and reverse phase in the second dimension to determine CBD and delta 9-THC in plasma samples from patients with PD being treated with CBD. Changes in the endocannabinoid system (AEA and 2AG) of PD patients will be evaluated, to find out whether the use of cannabidiol use alters the levels of these substances. The administered CBD doses will be correlated with CBD and delta 9-THC plasma concentrations in patients with PD. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |